Adam Conway

206-389-4554
aconway@fenwick.com
Associate
Corporate

Adam
Conway

Adam
Conway

Adam
Conway

Associate
Corporate
Industries

Adam provides strategic counseling to emerging and high-growth life sciences and technology companies —ranging from early-stage startups to mature, publicly traded corporations—in both day-to-day matters and a wide range of corporate transactions, including formations, venture capital financings, mergers and acquisitions, and public offerings. Adam also advises on various general corporate and securities law matters, including corporate governance best practices, compliance with stock exchange rules and securities laws, and periodic reporting obligations.

During law school, Adam was a staff editor for the Berkeley Business Law Journal and a member of Berkeley Law’s New Business Counseling Practicum. Adam also served as a judicial extern for the U.S. District Court for the Northern District of California.

  • Abdera Therapeutics
  • Attovia Therapeutics
  • BioAge Labs
  • Day One Biopharmaceuticals
  • EpiBiologics
  • Escient Pharmaceuticals
  • GoPro
  • Impel Pharmaceuticals
  • Lycia Therapeutics
  • Nomic AI
  • Passage Bio
  • Scribe Therapeutics
  • Stoke Therapeutics
  • Smartsheet
  • Sutro Biopharma
  • Third Harmonic Bio
  • Treeline Biosciences
  • Umoja Biopharma

  • Abdera Therapeutics
  • Attovia Therapeutics
  • BioAge Labs
  • Day One Biopharmaceuticals
  • EpiBiologics
  • Escient Pharmaceuticals
  • GoPro
  • Impel Pharmaceuticals
  • Lycia Therapeutics
  • Nomic AI
  • Passage Bio
  • Scribe Therapeutics
  • Stoke Therapeutics
  • Smartsheet
  • Sutro Biopharma
  • Third Harmonic Bio
  • Treeline Biosciences
  • Umoja Biopharma

  • AKASA in its $60M Series B financing
  • Augmedix in its $25M private placement and reverse merger with Malo Holdings Corp.
  • BioAge Labs in its initial $238M upsized initial public offering and concurrent private placement
  • Day One Biopharmaceuticals in its $184M initial public offering
  • Elevation Oncology in its PIPE offering
  • Icertis in its $80M Series F financing
  • Neoleukin in its $86.2M public offering
  • Outreach in its $200M Series G financing
  • Passage Bio in its $154M initial public offering and follow-on offerings
  • Smartsheet in its $8.4B acquisition by Blackstone and Vista Equity Partners
  • Stoke Therapeutics in its $125M upsized follow-on public offering
  • Sutro Biopharma in its follow-on offerings
  • Third Harmonic in its $213.1M upsized initial public offering
  • Umoja Biopharma in its $100M Series C financing

  • AKASA in its $60M Series B financing
  • Augmedix in its $25M private placement and reverse merger with Malo Holdings Corp.
  • BioAge Labs in its initial $238M upsized initial public offering and concurrent private placement
  • Day One Biopharmaceuticals in its $184M initial public offering
  • Elevation Oncology in its PIPE offering
  • Icertis in its $80M Series F financing
  • Neoleukin in its $86.2M public offering
  • Outreach in its $200M Series G financing
  • Passage Bio in its $154M initial public offering and follow-on offerings
  • Smartsheet in its $8.4B acquisition by Blackstone and Vista Equity Partners
  • Stoke Therapeutics in its $125M upsized follow-on public offering
  • Sutro Biopharma in its follow-on offerings
  • Third Harmonic in its $213.1M upsized initial public offering
  • Umoja Biopharma in its $100M Series C financing